Skip to main content

Table 1 Gal3 expression according to clinicopathologic variables

From: Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells

Variable

Total patients

High Gal3

Low Gal3

Age

 

p = 0.41

 

 20–35 yr

7

2

5

 36–50 yr

48

12

36

 51–70 yr

31

9

22

  > 70 yr

1

0

1

Race

 

p = 0.25

 

 Black

7

3

4

 White

61

18

43

 Hispanic

14

2

12

 Other

5

0

5

Menopausal status

 

p = 0.57

 

 Pre

47

13

34

 Post

37

10

27

 Unknown

3

0

3

pT stage

 

p = 0.22

 

 pT1 (0–2 cm)

22

9

13

 pT2 (2–5 cm)

55

13

42

 pT3 (>5 cm)

7

1

6

 Unknown

3

0

3

Tumor grade

 

p = 0.41

 

 1

5

2

3

 2

38

12

26

 3

44

9

35

pN stage

 

p = 0.36

 

 N1 (1–3 LN)

60

16

44

 N2 (4–9 LN)

19

5

14

 N3 (>9 LN)

8

2

6

Lymphovascular invasion

 

p = 0.01

 

 Present

38

5

33

 Absent

49

18

31

ER

 

p = 0.56

 

 Positive

53

13

40

 Negative

33

10

23

 Unknown

1

0

1

PR

 

p = 0.37

 

 Positive

40

9

31

 Negative

45

14

31

 Unknown

2

0

2

HER2

 

p = 0.21

 

 0

48

13

35

 1+

13

2

11

 2+

5

0

5

 3+

20

8

12

 Unknown

1

0

1

  1. Gal3 galectin-3, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor